.jpg)
.png)
Spring 2023
Overweight and obesity rates continue to climb worldwide, contributing to significant morbidity and mortality, despite several effective pharmacotherapy treatments that are grossly underutilized. Obesity is a major health problem with a US prevalence of 42.4% in adults and 19.3% in children.1 It... more
Lipid lowering therapy is a cornerstone of cardiovascular risk reduction. However, withholding or stopping lipid lowering therapy may be worth consideration in some individuals. These include elderly patients with comorbidities limiting life expectancy, individuals with a coronary artery calcium... more
The characterization and treatment of severe hypercholesterolemia among patients within large health systems have been studied extensively.1-6 However, little is known about the burden of disease at charity based or community clinics. These types of clinics often provide care for underserved,... more
The Southwest Lipid Association (SWLA) would like to thank all the contributing authors and editors for another edition of LipidSpin. Most importantly, SWLA and its board would like to thank all NLA members for their contributions, pushing boundaries, promoting healthier communities, and fostering... more
As President-Elect of the Pacific Lipid Association (PLA), I am super excited to share with you that the 2023 year is off to a great start! This issue of LipidSpin is a collaboration between PLA and SWLA with a focus on Pushing Boundaries. My immense gratitude goes out to all who have contributed.... more
Dr. Scott Kirkpatrick is SWLA’s 2022 Lipid Scholarship Program recipient, a PGY-5 cardiology fellow at the University of Arizona-Tuscon. As a future general cardiologist with a passion for preventive cardiology, his career mission is to help as many people as he can in the fight against... more
h1.page-header span { font-weight: 700; } New to LipidSpin! Post your completed crossword on social media and tag @nationallipid on Twitter, Facebook, and Instagram! If you are participating in the Pentathlon Challenge, you will earn 60 points for your social post! Click here to ... more
Lipoprotein(a) [Lp(a)] is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD). Although approximately 20% of the population has elevated Lp(a) levels (≥ 50 mg/dL or 125 nmol/L), there are currently no approved targeted medical treatments available. Lp(a) has a unique... more
WARM UP FOR THE NLA’S PENTATHLON CHALLENGE The NLA is excited to announce the Pentathlon Challenge, as we “Aim for Atlanta” and the 2023 Scientific Sessions. The Pentathlon Challenge is Olympic-inspired and consists of free and for-purchase activities from January 1, 2023,... more
This issue is sponsored by the Southwest and Pacific Lipid Associations